JP2022058799A - 酵素の内部移行のための組成物および方法 - Google Patents
酵素の内部移行のための組成物および方法 Download PDFInfo
- Publication number
- JP2022058799A JP2022058799A JP2022012834A JP2022012834A JP2022058799A JP 2022058799 A JP2022058799 A JP 2022058799A JP 2022012834 A JP2022012834 A JP 2022012834A JP 2022012834 A JP2022012834 A JP 2022012834A JP 2022058799 A JP2022058799 A JP 2022058799A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- protein
- enzyme
- antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 208
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 208
- 238000000034 method Methods 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 103
- 230000000694 effects Effects 0.000 claims abstract description 76
- 210000003712 lysosome Anatomy 0.000 claims abstract description 63
- 230000001868 lysosomic effect Effects 0.000 claims abstract description 63
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract description 57
- 230000002132 lysosomal effect Effects 0.000 claims abstract description 55
- 229940088598 enzyme Drugs 0.000 claims description 206
- 108090000623 proteins and genes Proteins 0.000 claims description 125
- 102000004169 proteins and genes Human genes 0.000 claims description 120
- 235000018102 proteins Nutrition 0.000 claims description 118
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 86
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 79
- 102000005962 receptors Human genes 0.000 claims description 73
- 108020003175 receptors Proteins 0.000 claims description 73
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 70
- 102100025222 CD63 antigen Human genes 0.000 claims description 68
- 229920002527 Glycogen Polymers 0.000 claims description 64
- 229940096919 glycogen Drugs 0.000 claims description 64
- 102000025171 antigen binding proteins Human genes 0.000 claims description 61
- 108091000831 antigen binding proteins Proteins 0.000 claims description 61
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 60
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 41
- 102100029000 Prolactin receptor Human genes 0.000 claims description 37
- 108010002519 Prolactin Receptors Proteins 0.000 claims description 34
- 108010052285 Membrane Proteins Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 28
- 102100032832 Integrin alpha-7 Human genes 0.000 claims description 27
- 102100039459 Myelin and lymphocyte protein Human genes 0.000 claims description 27
- 108010024084 integrin alpha7 Proteins 0.000 claims description 27
- 108010044467 Isoenzymes Proteins 0.000 claims description 26
- 108090000420 L-Type Calcium Channels Proteins 0.000 claims description 26
- 102000004016 L-Type Calcium Channels Human genes 0.000 claims description 26
- 210000003205 muscle Anatomy 0.000 claims description 26
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 25
- 102000018697 Membrane Proteins Human genes 0.000 claims description 25
- 239000012190 activator Substances 0.000 claims description 25
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 25
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 22
- 108060003951 Immunoglobulin Proteins 0.000 claims description 21
- 238000009825 accumulation Methods 0.000 claims description 21
- 102000018358 immunoglobulin Human genes 0.000 claims description 21
- 208000024720 Fabry Disease Diseases 0.000 claims description 20
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 claims description 18
- 102100040473 Leucine-rich repeat-containing protein 14B Human genes 0.000 claims description 18
- 101710198746 Leucine-rich repeat-containing protein 14B Proteins 0.000 claims description 18
- 102100035477 Popeye domain-containing protein 3 Human genes 0.000 claims description 18
- 101710192785 Popeye domain-containing protein 3 Proteins 0.000 claims description 18
- 102000053764 Sodium channel subunit beta-1 Human genes 0.000 claims description 18
- 108700039410 Sodium channel subunit beta-1 Proteins 0.000 claims description 18
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims description 18
- 102100040613 Uromodulin Human genes 0.000 claims description 18
- 108010027007 Uromodulin Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 claims description 17
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 claims description 17
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 16
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 16
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 claims description 15
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 claims description 14
- 101001053257 Homo sapiens DCC-interacting protein 13-beta Proteins 0.000 claims description 13
- 108060007951 sulfatase Proteins 0.000 claims description 13
- 102100024153 Cadherin-15 Human genes 0.000 claims description 12
- 150000003408 sphingolipids Chemical class 0.000 claims description 11
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 claims description 10
- 108010078791 Carrier Proteins Proteins 0.000 claims description 10
- 101000785944 Homo sapiens Asialoglycoprotein receptor 1 Proteins 0.000 claims description 10
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims description 10
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 102100030913 Acetylcholine receptor subunit alpha Human genes 0.000 claims description 9
- 102100022729 Acetylcholine receptor subunit delta Human genes 0.000 claims description 9
- 102100031491 Arylsulfatase B Human genes 0.000 claims description 9
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 claims description 9
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 9
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims description 9
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims description 9
- 102000053028 CD36 Antigens Human genes 0.000 claims description 9
- 108010045374 CD36 Antigens Proteins 0.000 claims description 9
- 102100024151 Cadherin-16 Human genes 0.000 claims description 9
- 102100039585 Claudin-16 Human genes 0.000 claims description 9
- 108091006027 G proteins Proteins 0.000 claims description 9
- 102000030782 GTP binding Human genes 0.000 claims description 9
- 108091000058 GTP-Binding Proteins 0.000 claims description 9
- 101000726895 Homo sapiens Acetylcholine receptor subunit alpha Proteins 0.000 claims description 9
- 101000678765 Homo sapiens Acetylcholine receptor subunit delta Proteins 0.000 claims description 9
- 101000785948 Homo sapiens Asialoglycoprotein receptor 2 Proteins 0.000 claims description 9
- 101000762246 Homo sapiens Cadherin-16 Proteins 0.000 claims description 9
- 101000888608 Homo sapiens Claudin-16 Proteins 0.000 claims description 9
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 claims description 9
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims description 9
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims description 9
- 101001039207 Homo sapiens Low-density lipoprotein receptor-related protein 8 Proteins 0.000 claims description 9
- 101001036448 Homo sapiens Myelin and lymphocyte protein Proteins 0.000 claims description 9
- 102000000853 LDL receptors Human genes 0.000 claims description 9
- 108010001831 LDL receptors Proteins 0.000 claims description 9
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 claims description 9
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims description 9
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims description 9
- 102100040705 Low-density lipoprotein receptor-related protein 8 Human genes 0.000 claims description 9
- 101710183596 Myelin and lymphocyte protein Proteins 0.000 claims description 9
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims description 9
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 108091006747 SLC22A13 Proteins 0.000 claims description 9
- 108091006269 SLC5A2 Proteins 0.000 claims description 9
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims description 9
- 102100021478 Solute carrier family 22 member 13 Human genes 0.000 claims description 9
- 102000004357 Transferases Human genes 0.000 claims description 9
- 108090000992 Transferases Proteins 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 9
- 230000012202 endocytosis Effects 0.000 claims description 9
- 102000006815 folate receptor Human genes 0.000 claims description 9
- 108020005243 folate receptor Proteins 0.000 claims description 9
- 108010087860 glutathione receptor Proteins 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 8
- 101710106740 Alpha-N-acetylglucosaminidase Proteins 0.000 claims description 8
- 102000004201 Ceramidases Human genes 0.000 claims description 8
- 108090000751 Ceramidases Proteins 0.000 claims description 8
- 108010060309 Glucuronidase Proteins 0.000 claims description 8
- 102000053187 Glucuronidase Human genes 0.000 claims description 8
- 102000001974 Hyaluronidases Human genes 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 8
- 101710202061 N-acetyltransferase Proteins 0.000 claims description 8
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 claims description 8
- 101710145697 Saposin-C Proteins 0.000 claims description 8
- 102000005262 Sulfatase Human genes 0.000 claims description 8
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 8
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 8
- 108010029607 4-nitrophenyl-alpha-glucosidase Proteins 0.000 claims description 7
- 102100026277 Alpha-galactosidase A Human genes 0.000 claims description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 7
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 7
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 claims description 7
- 102100036592 Neutral alpha-glucosidase AB Human genes 0.000 claims description 7
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims description 7
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims description 7
- 229960002773 hyaluronidase Drugs 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 101001072765 Homo sapiens Neutral alpha-glucosidase AB Proteins 0.000 claims description 6
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 claims description 6
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 208000010346 Sphingolipidoses Diseases 0.000 claims description 6
- 201000001307 Sphingolipidosis Diseases 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 108010076477 haematoside synthetase Proteins 0.000 claims description 6
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 6
- 108091006112 ATPases Proteins 0.000 claims description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 5
- 102000009133 Arylsulfatases Human genes 0.000 claims description 5
- 241000282836 Camelus dromedarius Species 0.000 claims description 5
- 241000251730 Chondrichthyes Species 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 230000003325 follicular Effects 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 239000000710 homodimer Substances 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 claims description 4
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 4
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 claims description 4
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 claims description 4
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 4
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000006515 AB Variant Tay-Sachs Disease Diseases 0.000 claims description 3
- 208000009796 Gangliosidoses Diseases 0.000 claims description 3
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims description 3
- 208000021811 Sandhoff disease Diseases 0.000 claims description 3
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 claims description 3
- 208000008291 Type B Niemann-Pick Disease Diseases 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 201000006440 gangliosidosis Diseases 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims description 3
- 208000035374 Chronic visceral acid sphingomyelinase deficiency Diseases 0.000 claims description 2
- 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims description 2
- 201000000794 Niemann-Pick disease type A Diseases 0.000 claims description 2
- 201000000791 Niemann-Pick disease type B Diseases 0.000 claims description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 5
- 108091008803 APLNR Proteins 0.000 claims 4
- 102000016555 Apelin receptors Human genes 0.000 claims 4
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 3
- 102100024398 DCC-interacting protein 13-beta Human genes 0.000 claims 2
- 241000402754 Erythranthe moschata Species 0.000 claims 2
- 101000910759 Homo sapiens Voltage-dependent calcium channel gamma-1 subunit Proteins 0.000 claims 2
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 claims 2
- 102100036197 Prosaposin Human genes 0.000 claims 2
- 102100024142 Voltage-dependent calcium channel gamma-1 subunit Human genes 0.000 claims 2
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 claims 1
- 239000012636 effector Substances 0.000 abstract description 78
- 230000027455 binding Effects 0.000 abstract description 43
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 230000005945 translocation Effects 0.000 description 70
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 40
- 239000000427 antigen Substances 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 28
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 23
- 230000004048 modification Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- 230000035508 accumulation Effects 0.000 description 20
- 239000000758 substrate Substances 0.000 description 18
- 102000009660 Cholinergic Receptors Human genes 0.000 description 17
- 238000001262 western blot Methods 0.000 description 17
- 102000014914 Carrier Proteins Human genes 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 102000004882 Lipase Human genes 0.000 description 15
- 108090001060 Lipase Proteins 0.000 description 15
- 108091008324 binding proteins Proteins 0.000 description 15
- 210000002027 skeletal muscle Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 239000004367 Lipase Substances 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 12
- 235000019421 lipase Nutrition 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 10
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 10
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 238000002641 enzyme replacement therapy Methods 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 102100037904 CD9 antigen Human genes 0.000 description 9
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 9
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 9
- 102100027918 Sucrase-isomaltase, intestinal Human genes 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- -1 mannose oligosaccharide Chemical class 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 102400000831 Saposin-C Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 102000004157 Hydrolases Human genes 0.000 description 5
- 108090000604 Hydrolases Proteins 0.000 description 5
- 102000056067 N-acetylglucosamine-6-sulfatases Human genes 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000001163 endosome Anatomy 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 4
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 4
- 101710099863 N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 description 4
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000007345 glycogen storage disease Diseases 0.000 description 4
- 238000011577 humanized mouse model Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 108010019813 leptin receptors Proteins 0.000 description 4
- 102000005861 leptin receptors Human genes 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 102000014452 scavenger receptors Human genes 0.000 description 4
- 108010078070 scavenger receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004683 skeletal myoblast Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- YUDPTGPSBJVHCN-JZYAIQKZSA-N 4-Methylumbelliferyl-alpha-D-glucopyranoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-JZYAIQKZSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000015872 Gaucher disease Diseases 0.000 description 3
- 102000004366 Glucosidases Human genes 0.000 description 3
- 108010056771 Glucosidases Proteins 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000003939 Membrane transport proteins Human genes 0.000 description 3
- 108090000301 Membrane transport proteins Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 210000003412 trans-golgi network Anatomy 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 108010008177 Fd immunoglobulins Proteins 0.000 description 2
- 102100023364 Ganglioside GM2 activator Human genes 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 2
- 101000685969 Homo sapiens Ganglioside GM2 activator Proteins 0.000 description 2
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 2
- 108010018562 M-cadherin Proteins 0.000 description 2
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000188 diaphragm Anatomy 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000057640 human CD63 Human genes 0.000 description 2
- 102000043404 human GLA Human genes 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 101150002688 kremen1 gene Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010045758 lysosomal proteins Proteins 0.000 description 2
- 230000009061 membrane transport Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 1
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 1
- BTENASAGUCBJAU-UHFFFAOYSA-N 2-aminoacetic acid;carbon dioxide Chemical compound O=C=O.NCC(O)=O BTENASAGUCBJAU-UHFFFAOYSA-N 0.000 description 1
- JUAGNSFMKLTCCT-UHFFFAOYSA-N 2-aminoacetic acid;carbonic acid Chemical compound OC(O)=O.NCC(O)=O JUAGNSFMKLTCCT-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 101710196722 Alpha-glucosidase 2 Proteins 0.000 description 1
- 101710168921 Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101150001853 CD63 gene Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101100480905 Escherichia phage P1 tec gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 101150115151 GAA gene Proteins 0.000 description 1
- 208000037326 Gaucher disease type 1 Diseases 0.000 description 1
- 101150014526 Gla gene Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010058102 Glycogen Debranching Enzyme System Proteins 0.000 description 1
- 102000006263 Glycogen Debranching Enzyme System Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 1
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000031942 Late Onset disease Diseases 0.000 description 1
- 208000033868 Lysosomal disease Diseases 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100176189 Mus musculus Gnl1 gene Proteins 0.000 description 1
- 101100405128 Mus musculus Nr4a3 gene Proteins 0.000 description 1
- 101100480907 Mus musculus Tec gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 108010040066 N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 101710140639 Neutral alpha-glucosidase AB Proteins 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100077260 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MMR1 gene Proteins 0.000 description 1
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010077678 Tetraspanin 30 Proteins 0.000 description 1
- 102000010428 Tetraspanin 30 Human genes 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 201000009431 angiokeratoma Diseases 0.000 description 1
- 206010002512 anhidrosis Diseases 0.000 description 1
- 230000037001 anhydrosis Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013003 endocytic recycling Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 description 1
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 108010014657 sortilin Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000040811 transporter activity Human genes 0.000 description 1
- 108091092194 transporter activity Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 150000008496 α-D-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2445—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04041—Sphingomyelin phosphodiesterase D (3.1.4.41)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本発明は、記載された特定の実施形態、組成物、方法、および実験条件に限定されるものではないが、それはこうした実施形態、組成物、方法、および条件が異なる場合があるからである。本発明の範囲が添付の特許請求の範囲のみによって限定されるものである以上、本明細書に使用される用語は、特定の実施形態を説明する目的のためだけのものであり、限定することを意図するものではない。
CI-MPR非依存抗体誘導送達系を、酵素をリソソームに送達するように設計した。表3には、分子構築物を列挙し、それらのCHO細胞内発現レベル(図2を参照)、蛍光基質4-メチルウンベリフェリル-α-グルコシドを用いて測定されたおおよそのGAA活性(図3を参照)、ならびにリソソーム標的指向化、内部移行、および活性状態(図4および図5を参照)を示している。
GAA構築物の内部移行を、細胞可溶化物における酵素活性を測定することにより定量した。組換えGAA(配列番号1)の種々の構築物を、HEK293、ヒト骨格筋芽細胞(Lonza、メリーランド州ウォーカーズビル)、または、C2C12マウス筋芽細胞に添加した。酵素構築物の添加の24時間前に、細胞を24ウェルプレートにプレーティングした。酵素構築物を細胞の培地に18時間添加した。続いて、細胞を氷冷PBS中にて十分に洗浄し、氷冷した0.5% NP-40のアッセイ緩衝液(0.2Mの酢酸ナトリウム、0.4Mの塩化カリウム、pH4.3)中で溶解した。溶解物を4℃にて15,000×gで15分間遠心分離し、上清をGAA基質である4-メチルウンベリフェリルアルファ-D-グルコシドと共に、96ウェルプレートでアッセイ緩衝液中にて1時間インキュベートした。グリシン-炭酸緩衝液を用いてpH10.7で反応を停止した。蛍光を、励起波長360nmおよび発光波長450nmにおいてプレートリーダーで読み取った。溶解物のタンパク質濃度を、ビシンコニン酸アッセイキットを用いて定量した。4-メチルウンベリフェロンを基質として用いた。GAA活性を、精製タンパク質1mg当たりに毎時放出される4-メチルウンベリフェロンのnmol数として記録した。Fuller et al.,“Isolation and characterisation of a recombinant,precursor form of lysosomal acid alpha-glucosidase,”234(3)European Journal of Biochemistry 903-909(1995)を参照されたい。
骨格筋芽細胞(ポンペ病における検討対象の組織タイプ)が種々のGAA構築物を取り込む能力を評価した。種々の濃度(すなわち、25nM、50nM、および200nM)の(1)抗CD63-GAA、(2)抗CD63-GAA+5mM M6P、(3)myc-GAA、および(4)myc-GAA+5mM M6Pの存在下、ヒト骨格筋芽細胞を培養した。GAA構築物の内部移行を、4-メチルウンベリフェロンの蓄積によって示される細胞可溶化物で検出したGAA活性レベルから推測し、評価した。200nMのMPR非依存性抗CD63-GAAの取り込み量は、MPR依存性のmyc-GAAの取り込み量よりも5倍超多かった(図5A)。
抗CD63-GAAが3つの異なる種類のポンペ細胞株のリソソームにおいてグリコーゲン蓄積に及ぼす影響を評価した。ポンペ細胞株は、重症の乳児型ポンペ病を発症した患者から得られた線維芽細胞由来であり、GAA遺伝子においてノックアウト変異またはノックダウン変異を含んでいた。使用した細胞株は、GM20089(エクソン18欠失)、GM20090(エクソン14およびエクソン16における複合ヘテロ接合体)、およびGM20090(エクソン2における複合ヘテロ接合体)であった。これらの細胞株をCoriell Institute(ニュージャージー州カムデン)から得た。Huie et al.,“Increased occurrence of cleft lip in glycogen storage disease type II(GSDII):exclusion of a contiguous gene syndrome in two patients by presence of intragenic mutations including a novel nonsense mutation Gln58Stop,”85(1)Am.J.Med.Genet.5-8(1999);Huie et al.,“Glycogen storage disease type II:identification of four novel missense mutations(D645N,G648S,R672W,R672Q)and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype,”244(3)Biochem.Biophys.Res.Commun.921-7(1998)and;Nishiyama et al.,“Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease,”107 Molecular genetics and metabolism 490-5(2012)を参照されたい。新生児ヒト皮膚線維芽(NHDF、Lonza)を対照として用いた。全てのポンペ細胞株は、残留(<0.1%)GAA活性が存在する場合でも、リソソームグリコーゲン蓄積を示した(細胞質内グリコーゲンを低減させるグルコース飢餓の72時間後)(図6、パネルAおよびパネルB)。グリコーゲンをグリコーゲンアッセイキット(Sigma-Aldrich、ミズーリ州セントルイス)を用いて測定した。
GAA(すなわち、交差反応免疫学的物質またはCRIM)に対して起こり得るポンペ患者の免疫応答を回避するために、GAA活性を救済する他のヒトグルコシダーゼを送達することを検討した。GAA(別名は酸性α-グルコシダーゼ)に対して同様のグリコーゲン加水分解活性を有する非リソソーム酵素を調べた。これらの酵素として、スクラーゼ・イソマルターゼ(SI)、マルターゼ・グルコアミラーゼ(MGAM)、グルコシダーゼII(GANAB)、および中性α-グルコシダーゼ(C GNAC)が挙げられる。これらの酵素および種々の組換え実施形態が、Dhital et al.,“Mammalian mucosal α-glucosidases coordinate with α-amylase in the initial starch hydrolysis stage to have a role in starch digestion beyond glucogenesis,”8(4)PLoS One e625462013 Apr 25(2013);Sim et al.,“Human intestinal maltase-glucoamylase:crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity,”375(3)J.Mol.Biol.782-92(2008);およびQuezada-Calvillo et al.,“Luminal starch substrate “brake”on maltase-glucoamylase activity is located within the glucoamylase subunit,”138(4)J.Nutr.685-92(2008)に記載されている。
ヒトGLA(配列番号2)を含む種々の融合タンパク質を構築し、CHO細胞内で発現させた。これらの構築物には、(i)抗CD63重鎖のC末端に融合したGLA(抗CD63-GLA)、(ii)イムノグロブリンFcに融合したGLA(例えば、Fc「ノブ」)、(iii)GLA-抗CD63(すなわち、抗CD63重鎖のN末端に融合したGLA)、および(iv)GLA-myc融合を含めた(図8)。また、GLA部分のない内部移行エフェクター結合タンパク質(IEBP)を、改変かつ発現させた。一例では、IEBPは、CD63に対する結合特異性を持つ一方の半分と、mycに対する結合特異性を持つ他方の半分を備えた二重特異性抗体であった。GLA酵素活性(すなわち、4-メチルウンベリフェリル-β-ガラクトピラノシドの加水分解)を各GLA融合タンパク質に対して評価し、その結果を図9に示す。全構築物は、C末端抗CD63-GLA融合を除外して、α-ガラクトシダーゼ活性を示した(図9)。Fcノブについては、Ridgway et al.,“‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,”9(7)Protein Eng.617-621(1996)に記載されている。
抗CD63抗体または抗APLP2抗体の低pH細胞分画への内部移行を、高M6P含有量を有している、組換えヒトGLA(rhGLA)の低pH分画への内部移行と比較した。GLA、抗CD63、および抗APLP2の各々を、低pH感受性色素pHrodo(登録商標)(Invitrogen、カリフォルニア州カールスバッド)で標識した。HEK細胞、HepG2細胞(肝癌)、およびPC-3細胞(前立腺癌)をpHrodo(登録商標)で標識したタンパク質と接触させ、一晩または約16時間インキュベートした。続いて、細胞をイメージングし、蛍光小胞をカウントした。各タンパク質の標識度合いに応じて蛍光出力を標準化した。HEK細胞、PC-3細胞、およびHepG2細胞は、rhGLAに比べて抗CD63と抗APLP2の取り込み量がより多くなることを示した(図11)。
抗CD63-GAA構築物がリソソーム内でタンパク質分解的にプロセシングされるか否かを、ポンペ細胞可溶化物のウェスタンブロット分析により評価した。GM20089ポンペ細胞を抗CD63-GAAの存在下で培養し、生じた細胞可溶化物を、抗GAA抗体(図12、パネルA)または抗hIgG抗体(図12、パネルB)を用いて還元ウェスタンブロット分析した。
CD63部位でヒト化されたマウス(Valenzuela et al.,“High-throughput engineering of the mouse genome coupled with high-resolution expression analysis,”21 Nature Biotechnology 652 - 659(2003)を参照)に抗CD63-GAAを投与した。組織サンプルを採取し、GAAをウェスタンブロット分析により評価した。GAAは、肝臓、横隔膜、腎臓、心臓、ならびに四頭筋および腓腹筋で検出された(図13)。
筋特異的抗原(抗インテグリンアルファ7、抗CD9、および抗ジストログリカン)に対するビオチン化抗体をGAAノックアウトマウスに投与した。これらの抗体の組織分布をウェスタンブロット分析により測定した。図15には、骨格筋(腓腹筋、四頭筋、および横隔膜)、心筋、肝臓(標準化用のベースラインとして機能する)、腎臓、および脾臓内で見られた抗体レベルのヒストグラムを示す。抗インテグリンアルファ7抗体は、骨格筋および心臓で(肝臓で見られたレベルを上回るレベルで)見られた。抗CD9抗体は骨格筋および心臓で(肝臓で見られたレベルを上回るレベルで)見られ、また腎臓および脾臓でも同様に見られた(図15)。
天然マウスCD63発現を有する2~3月齢のGAAノックアウト(KO)マウスに、完全長ヒトα-グルコシダーゼ(hGAA)、抗mCD63-GAA(抗マウスCD63)およびその関連軽鎖、または抗hCD63-GAA(抗ヒトCD63)およびその関連軽鎖をコードするプラスミド構築物を流体力学的送達(HDD)した。全ての構築物は、ユビキチンプロモーターとSV40polyAテールとからなる同一のプラスミドバックボーンを用いた。簡単に述べると、各プラスミドの40μg(すなわち、重鎖と軽鎖の40μgまたはhGAAのみの40μg)を滅菌生理食塩水2mL~3mLで希釈し、GAA KOマウスの尾静脈にすばやく注射した。3日毎の尾出血により、約10日間のhGAA構築物または抗体GAA構築物の血清レベルを明らかにした。マウスをHDDの3週間後に屠殺し、組織を液体窒素で急速凍結した。組織を蒸留水で均質化し、煮沸、遠心沈殿した。蛍光グリコーゲンアッセイキット(MAK016、Sigma Aldrich、ミズーリ州セントルイス)を用いて上清についてグリコーゲンの定量を行った。
リソソーム酸性リパーゼ(LALまたはLIPA)は、コレステリルエステルおよびトリグリセリドをリソソーム内で分解する酵素である。LIPAにおける欠損(例えば、LAL-Dまたはウォルマン病)は、肝臓、脾臓、および他の器官で脂肪質の蓄積をもたらす。LAL-Dの有病率は、世界で40,000人に1人~300,000人に1人である。LIPA欠損を持つ乳児は、処置されなければ、多臓器不全のために6か月~12か月で死亡する。より年長の子供は診断未確定のまま、心臓発作、脳卒中、または肝不全で死亡する可能性がある。
[本発明1001]
エンドサイトーシスを起こす膜タンパク質に結合する抗原結合タンパク質に直接、または単一のリンカーによって連結されているリソソーム酵素を含む、組成物。
[本発明1002]
前記膜タンパク質が、リソソーム膜に局在する、本発明1001の組成物。
[本発明1003]
前記リソソーム酵素が、α-ガラクトシダーゼ、β-ガラクトシダーゼ、α-グルコシダーゼ、β-グルコシダーゼ、サポシン-C活性化因子、セラミダーゼ、スフィンゴミエリナーゼ、β-ヘキソサミニダーゼ、GM2活性化因子、GM3シンターゼ、アリールスルファターゼ、スフィンゴ脂質活性化因子、α-イズロニダーゼ、イズロニダーゼ-2-スルファターゼ、ヘパリンN-スルファターゼ、N-アセチル-α-グルコサミニダーゼ、α-グルコサミドN-アセチルトランスフェラーゼ、N-アセチルグルコサミン-6-スルファターゼ、N-アセチルガラクトサミン-6-硫酸スルファターゼ、N-アセチルガラクトサミン-4-スルファターゼ、β-グルクロニダーゼ、およびヒアルロニダーゼからなる群から選択される、本発明1001の組成物。
[本発明1004]
前記抗原結合タンパク質が、受容体融合分子、トラップ分子、受容体Fc融合分子、抗体、Fab断片、F(ab’)2断片、Fd断片、Fv断片、一本鎖Fv(scFv)分子、dAb断片、単離相補性決定領域(CDR)、CDR3ペプチド、拘束FR3-CDR3-FR4ペプチド、ドメイン特異的抗体、単一ドメイン抗体、ドメイン欠失抗体、キメラ抗体、CDR移植抗体、ダイアボディ、トリアボディ、テトラボディ、ミニボディ、ナノボディ、一価ナノボディ、二価ナノボディ、小モジュラー免疫薬(SMIP:small modular immunopharmaceutical)、ラクダ抗体(VHH重鎖ホモ二量体抗体)、およびサメ可変IgNARドメインからなる群から選択される、本発明1001から本発明1003のうちのいずれかの組成物。
[本発明1005]
前記膜タンパク質が、CD63、MHC-I、Kremen-1、Kremen-2、LRP5、LRP6、LRP8、トランスフェリン受容体、LDL-受容体、LDL関連タンパク質1受容体、ASGR1、ASGR2、アミロイド前駆体タンパク質様タンパク質-2(APLP2)、アペリン受容体(APLNR)、PRLR(プロラクチン受容体)、MAL(Myelin And Lymphocyteタンパク質、別名VIP17)、IGF2R、液胞型H+ATPアーゼ、ジフテリア毒素受容体、葉酸受容体、グルタミン酸受容体、グルタチオン受容体、レプチン受容体、スカベンジャー受容体、SCARA1-5、SCARB1-3、CD36、CDH16(Cadheri-16)、CLDN16(Claudn-16)、KL(Klotho)、PTH1R(副甲状腺ホルモン受容体)、SLC22A13(溶質輸送体ファミリー22メンバー13)、SLC5A2(ナトリウム/グルコース共輸送体2)、UMOD(ウロモジュリン)、BMPR1A(骨形態形成タンパク質受容体1A)、m-カドヘリン、CD9、MuSK(筋特異的キナーゼ)、LGR4/GPR48(Gタンパク質共役受容体48)、コリン作動性受容体(ニコチン性)アルファ1、CDH15(Cadheri-15)、ITGA7(インテグリンアルファ-7)、CACNG1(L型カルシウムチャネルサブユニットガンマ-1)、CACNAls(L型カルシウムチャネルサブユニットアルファ-15)、CACNG6(L型カルシウムチャネルサブユニットガンマ-6)、SCN1B(ナトリウムチャネルサブユニットベータ-1)、CHRNA1(ACh受容体サブユニットアルファ)、CHRND(ACh受容体サブユニットデルタ)、LRRC14B(ロイシンリッチリピート含有タンパク質14B)、およびPOPDC3(Popeyeドメイン含有タンパク質3)からなる群から選択される、本発明1001から本発明1004のうちのいずれかの組成物。
[本発明1006]
前記リソソーム酵素が、前記抗原結合タンパク質に直接連結している、本発明1001から本発明1005のうちのいずれかの組成物。
[本発明1007]
前記抗原結合タンパク質が抗体を含み、前記酵素が前記抗体の重鎖のC末端に共有結合している、本発明1006の組成物。
[本発明1008]
前記リソソーム酵素が、単一のリンカーによって前記抗原結合タンパク質に連結している、本発明1001から本発明1005のうちのいずれかの組成物。
[本発明1009]
前記抗原結合タンパク質が半抗体を含み、前記リソソーム酵素がイムノグロブリンのFcドメインに共有結合し、前記酵素に共有結合した前記Fcドメインが、前記抗原結合タンパク質のFcドメインと結合している、本発明1008の組成物。
[本発明1010]
前記リンカーが開裂可能なリンカーである、本発明1008の組成物。
[本発明1011]
前記リソソーム酵素がGAAであるか、またはGAA活性を含み、前記膜タンパク質が、CD63、APLP2、およびPRLRからなる群から選択される、本発明1001から本発明1010のうちのいずれかの組成物。
[本発明1012]
前記リソソーム酵素がGAAであるか、またはGAA活性を含み、前記膜タンパク質がCD63である、本発明1001から本発明1011のうちのいずれかの組成物。
[本発明1013]
前記リソソーム酵素が配列番号1のアミノ酸配列を含む、本発明1001から本発明1012のうちのいずれかの組成物。
[本発明1014]
前記リソソーム酵素がGLAであるか、またはGLA活性を含み、前記膜タンパク質が、CD63、APLP2、およびPRLRからなる群から選択される、本発明1001から本発明1010のうちのいずれかの組成物。
[本発明1015]
前記酵素がGLAであるか、またはGLA活性を含み、前記膜タンパク質がCD63である、本発明1001から本発明1010および本発明1014のうちのいずれかの組成物。
[本発明1016]
前記リソソーム酵素が配列番号2のアミノ酸配列を含む、本発明1001から本発明1010、本発明1014、および本発明1015のうちのいずれかの組成物。
[本発明1017]
リソソーム蓄積症(LSD)に罹患している対象を治療する方法であって、
前記対象に(a)酵素と(b)エンドサイトーシスを起こす膜タンパク質に結合する抗原結合タンパク質とを含む生物学的治療用複合体を投与することを含み、
前記生物学的治療用複合体が、前記対象の細胞のリソソームに入って、前記リソソームに前記酵素を送達し、それが前記LSDに関連する酵素活性(「内因性酵素」)を補充する、前記方法。
[本発明1018]
前記LSDが、スフィンゴリピドーシス、ムコ多糖症、およびグリコーゲン蓄積症からなる群から選択される、本発明1017の方法。
[本発明1019]
前記LSDが、ファブリー病、ゴーシェ病I型、ゴーシェ病II型、ゴーシェ病III型、ニーマン・ピック病A型、ニーマン・ピック病B型、GM1-ガングリオシドーシス、サンドホフ病、テイ・サックス病、GM2-活性化因子欠損、GM3-ガングリオシドーシス、異染性白質ジストロフィー、スフィンゴ脂質活性化因子欠損、シャイエ病、ハーラー・シャイエ病、ハーラー病、ハンター病、サンフィリポA、サンフィリポB、サンフィリポC、サンフィリポD、モルキオ症候群A、モルキオ症候群B、マロトー・ラミー病、スライ病、MPS IX、およびポンペ病からなる群から選択される、本発明1017または本発明1018の方法。
[本発明1020]
前記LSDがファブリー病またはポンペ病である、本発明1017から本発明1019のうちのいずれかの方法。
[本発明1021]
前記酵素が、α-ガラクトシダーゼ、β-ガラクトシダーゼ、α-グルコシダーゼ、β-グルコシダーゼ、サポシン-C活性化因子、セラミダーゼ、スフィンゴミエリナーゼ、β-ヘキソサミニダーゼ、GM2活性化因子、GM3シンターゼ、アリールスルファターゼ、スフィンゴ脂質活性化因子、α-イズロニダーゼ、イズロニダーゼ-2-スルファターゼ、ヘパリンN-スルファターゼ、N-アセチル-α-グルコサミニダーゼ、α-グルコサミドN-アセチルトランスフェラーゼ、N-アセチルグルコサミン-6-スルファターゼ、N-アセチルガラクトサミン-6-硫酸スルファターゼ、N-アセチルガラクトサミン-4-スルファターゼ、β-グルクロニダーゼ、およびヒアルロニダーゼからなる群から選択される、本発明1017の方法。
[本発明1022]
前記酵素が、前記対象において免疫反応を誘導しない、本発明1017から本発明1021のうちのいずれかの方法。
[本発明1023]
前記酵素がアイソザイムである、本発明1017から本発明1022のうちのいずれかの方法。
[本発明1024]
前記LSDがポンペ病であり、前記内因性酵素がα-グルコシダーゼ(GAA)であり、前記アイソザイムが、酸性α-グルコシダーゼ、スクラーゼ・イソマルターゼ(SI)、マルターゼ・グルコアミラーゼ(MGAM)、グルコシダーゼII(GANAB)、および中性α-グルコシダーゼ(C GNAC)からなる群から選択される、本発明1023の方法。
[本発明1025]
前記LSDがファブリー病であり、前記内因性酵素がα-ガラクトシダーゼA(GLA)であり、前記アイソザイムがGLA活性を得るように操作されたα-N-アセチルガラクトサミニダーゼである、本発明1023の方法。
[本発明1026]
前記膜タンパク質が、CD63、MHC-I、Kremen-1、Kremen-2、LRP5、LRP6、LRP8、トランスフェリン受容体、LDL-受容体、LDL関連タンパク質1受容体、ASGR1、ASGR2、アミロイド前駆体タンパク質様タンパク質-2(APLP2)、アペリン受容体(APLNR)、PRLR(プロラクチン受容体)、MAL(Myelin And Lymphocyteタンパク質、別名VIP17)、IGF2R、液胞型H+ATPアーゼ、ジフテリア毒素受容体、葉酸受容体、グルタミン酸受容体、グルタチオン受容体、レプチン受容体、スカベンジャー受容体、SCARA1-5、SCARB1-3、CD36、CDH16(Cadheri-16)、CLDN16(Claudn-16)、KL(Klotho)、PTH1R(副甲状腺ホルモン受容体)、SLC22A13(溶質輸送体ファミリー22メンバー13)、SLC5A2(ナトリウム/グルコース共輸送体2)、UMOD(ウロモジュリン)、BMPR1A(骨形態形成タンパク質受容体1A)、m-カドヘリン、CD9、MuSK(筋特異的キナーゼ)、LGR4/GPR48(Gタンパク質共役受容体48)、コリン作動性受容体(ニコチン性)アルファ1、CDH15(Cadheri-15)、ITGA7(インテグリンアルファ-7)、CACNG1(L型カルシウムチャネルサブユニットガンマ-1)、CACNAls(L型カルシウムチャネルサブユニットアルファ-15)、CACNG6(L型カルシウムチャネルサブユニットガンマ-6)、SCN1B(ナトリウムチャネルサブユニットベータ-1)、CHRNA1(ACh受容体サブユニットアルファ)、CHRND(ACh受容体サブユニットデルタ)、LRRC14B(ロイシンリッチリピート含有タンパク質14B)、およびPOPDC3(Popeyeドメイン含有タンパク質3)からなる群から選択される、本発明1017から本発明1025のうちのいずれかの方法。
[本発明1027]
前記膜タンパク質がCD63である、本発明1017から本発明1026のうちのいずれかの方法。
[本発明1028]
前記膜タンパク質がAPLP2である、本発明1017から本発明1026のうちのいずれかの方法。
[本発明1029]
前記抗原結合タンパク質が、抗体、抗体断片、または他の抗原結合タンパク質である、本発明1017から本発明1028のうちのいずれかの方法。
[本発明1030]
前記抗原結合タンパク質が、前記酵素と前記膜タンパク質とに結合する二重特異性抗体である、本発明1029の方法。
[本発明1031]
前記酵素がイムノグロブリンのFcドメインに連結しており、前記抗原結合タンパク質が半抗体を含む、本発明1017から本発明1029のうちのいずれかの方法。
[本発明1032]
前記酵素が、抗膜タンパク質抗体の前記重鎖のC末端に共有結合している、本発明1017から本発明1029のうちのいずれかの方法。
[本発明1033]
前記酵素が、抗膜タンパク質抗体の前記重鎖のN末端に共有結合している、本発明1017から本発明1029のうちのいずれかの方法。
[本発明1034]
前記酵素がGLAを含み、前記膜タンパク質がCD63であり、および前記LSDがファブリー病である、本発明1030の方法。
[本発明1035]
前記酵素がGAAを含み、前記膜タンパク質がCD63であり、および前記LSDがポンペ病である、本発明1030の方法。
Claims (35)
- エンドサイトーシスを起こす膜タンパク質に結合する抗原結合タンパク質に直接、または単一のリンカーによって連結されているリソソーム酵素を含む、組成物。
- 前記膜タンパク質が、リソソーム膜に局在する、請求項1に記載の組成物。
- 前記リソソーム酵素が、α-ガラクトシダーゼ、β-ガラクトシダーゼ、α-グルコシダーゼ、β-グルコシダーゼ、サポシン-C活性化因子、セラミダーゼ、スフィンゴミエリナーゼ、β-ヘキソサミニダーゼ、GM2活性化因子、GM3シンターゼ、アリールスルファターゼ、スフィンゴ脂質活性化因子、α-イズロニダーゼ、イズロニダーゼ-2-スルファターゼ、ヘパリンN-スルファターゼ、N-アセチル-α-グルコサミニダーゼ、α-グルコサミドN-アセチルトランスフェラーゼ、N-アセチルグルコサミン-6-スルファターゼ、N-アセチルガラクトサミン-6-硫酸スルファターゼ、N-アセチルガラクトサミン-4-スルファターゼ、β-グルクロニダーゼ、およびヒアルロニダーゼからなる群から選択される、請求項1に記載の組成物。
- 前記抗原結合タンパク質が、受容体融合分子、トラップ分子、受容体Fc融合分子、抗体、Fab断片、F(ab’)2断片、Fd断片、Fv断片、一本鎖Fv(scFv)分子、dAb断片、単離相補性決定領域(CDR)、CDR3ペプチド、拘束FR3-CDR3-FR4ペプチド、ドメイン特異的抗体、単一ドメイン抗体、ドメイン欠失抗体、キメラ抗体、CDR移植抗体、ダイアボディ、トリアボディ、テトラボディ、ミニボディ、ナノボディ、一価ナノボディ、二価ナノボディ、小モジュラー免疫薬(SMIP:small modular immunopharmaceutical)、ラクダ抗体(VHH重鎖ホモ二量体抗体)、およびサメ可変IgNARドメインからなる群から選択される、請求項1から請求項3のうちのいずれか1項に記載の組成物。
- 前記膜タンパク質が、CD63、MHC-I、Kremen-1、Kremen-2、LRP5、LRP6、LRP8、トランスフェリン受容体、LDL-受容体、LDL関連タンパク質1受容体、ASGR1、ASGR2、アミロイド前駆体タンパク質様タンパク質-2(APLP2)、アペリン受容体(APLNR)、PRLR(プロラクチン受容体)、MAL(Myelin And Lymphocyteタンパク質、別名VIP17)、IGF2R、液胞型H+ATPアーゼ、ジフテリア毒素受容体、葉酸受容体、グルタミン酸受容体、グルタチオン受容体、レプチン受容体、スカベンジャー受容体、SCARA1-5、SCARB1-3、CD36、CDH16(Cadheri-16)、CLDN16(Claudn-16)、KL(Klotho)、PTH1R(副甲状腺ホルモン受容体)、SLC22A13(溶質輸送体ファミリー22メンバー13)、SLC5A2(ナトリウム/グルコース共輸送体2)、UMOD(ウロモジュリン)、BMPR1A(骨形態形成タンパク質受容体1A)、m-カドヘリン、CD9、MuSK(筋特異的キナーゼ)、LGR4/GPR48(Gタンパク質共役受容体48)、コリン作動性受容体(ニコチン性)アルファ1、CDH15(Cadheri-15)、ITGA7(インテグリンアルファ-7)、CACNG1(L型カルシウムチャネルサブユニットガンマ-1)、CACNAls(L型カルシウムチャネルサブユニットアルファ-15)、CACNG6(L型カルシウムチャネルサブユニットガンマ-6)、SCN1B(ナトリウムチャネルサブユニットベータ-1)、CHRNA1(ACh受容体サブユニットアルファ)、CHRND(ACh受容体サブユニットデルタ)、LRRC14B(ロイシンリッチリピート含有タンパク質14B)、およびPOPDC3(Popeyeドメイン含有タンパク質3)からなる群から選択される、請求項1から請求項4のうちのいずれか1項に記載の組成物。
- 前記リソソーム酵素が、前記抗原結合タンパク質に直接連結している、請求項1から請求項5のうちのいずれか1項に記載の組成物。
- 前記抗原結合タンパク質が抗体を含み、前記酵素が前記抗体の重鎖のC末端に共有結合している、請求項6に記載の組成物。
- 前記リソソーム酵素が、単一のリンカーによって前記抗原結合タンパク質に連結している、請求項1から請求項5のうちのいずれか1項に記載の組成物。
- 前記抗原結合タンパク質が半抗体を含み、前記リソソーム酵素がイムノグロブリンのFcドメインに共有結合し、前記酵素に共有結合した前記Fcドメインが、前記抗原結合タンパク質のFcドメインと結合している、請求項8に記載の組成物。
- 前記リンカーが開裂可能なリンカーである、請求項8に記載の組成物。
- 前記リソソーム酵素がGAAであるか、またはGAA活性を含み、前記膜タンパク質が、CD63、APLP2、およびPRLRからなる群から選択される、請求項1から請求項10のうちのいずれか1項に記載の組成物。
- 前記リソソーム酵素がGAAであるか、またはGAA活性を含み、前記膜タンパク質がCD63である、請求項1から請求項11のうちのいずれか1項に記載の組成物。
- 前記リソソーム酵素が配列番号1のアミノ酸配列を含む、請求項1から請求項12のうちのいずれか1項に記載の組成物。
- 前記リソソーム酵素がGLAであるか、またはGLA活性を含み、前記膜タンパク質が、CD63、APLP2、およびPRLRからなる群から選択される、請求項1から請求項10のうちのいずれか1項に記載の組成物。
- 前記酵素がGLAであるか、またはGLA活性を含み、前記膜タンパク質がCD63である、請求項1から請求項10および請求項14のうちのいずれか1項に記載の組成物。
- 前記リソソーム酵素が配列番号2のアミノ酸配列を含む、請求項1から請求項10、請求項14、および請求項15のうちのいずれか1項に記載の組成物。
- リソソーム蓄積症(LSD)に罹患している対象を治療する方法であって、
前記対象に(a)酵素と(b)エンドサイトーシスを起こす膜タンパク質に結合する抗原結合タンパク質とを含む生物学的治療用複合体を投与することを含み、
前記生物学的治療用複合体が、前記対象の細胞のリソソームに入って、前記リソソームに前記酵素を送達し、それが前記LSDに関連する酵素活性(「内因性酵素」)を補充する、前記方法。 - 前記LSDが、スフィンゴリピドーシス、ムコ多糖症、およびグリコーゲン蓄積症からなる群から選択される、請求項17に記載の方法。
- 前記LSDが、ファブリー病、ゴーシェ病I型、ゴーシェ病II型、ゴーシェ病III型、ニーマン・ピック病A型、ニーマン・ピック病B型、GM1-ガングリオシドーシス、サンドホフ病、テイ・サックス病、GM2-活性化因子欠損、GM3-ガングリオシドーシス、異染性白質ジストロフィー、スフィンゴ脂質活性化因子欠損、シャイエ病、ハーラー・シャイエ病、ハーラー病、ハンター病、サンフィリポA、サンフィリポB、サンフィリポC、サンフィリポD、モルキオ症候群A、モルキオ症候群B、マロトー・ラミー病、スライ病、MPS IX、およびポンペ病からなる群から選択される、請求項17または請求項18に記載の方法。
- 前記LSDがファブリー病またはポンペ病である、請求項17から請求項19のうちのいずれか1項に記載の方法。
- 前記酵素が、α-ガラクトシダーゼ、β-ガラクトシダーゼ、α-グルコシダーゼ、β-グルコシダーゼ、サポシン-C活性化因子、セラミダーゼ、スフィンゴミエリナーゼ、β-ヘキソサミニダーゼ、GM2活性化因子、GM3シンターゼ、アリールスルファターゼ、スフィンゴ脂質活性化因子、α-イズロニダーゼ、イズロニダーゼ-2-スルファターゼ、ヘパリンN-スルファターゼ、N-アセチル-α-グルコサミニダーゼ、α-グルコサミドN-アセチルトランスフェラーゼ、N-アセチルグルコサミン-6-スルファターゼ、N-アセチルガラクトサミン-6-硫酸スルファターゼ、N-アセチルガラクトサミン-4-スルファターゼ、β-グルクロニダーゼ、およびヒアルロニダーゼからなる群から選択される、請求項17に記載の方法。
- 前記酵素が、前記対象において免疫反応を誘導しない、請求項17から請求項21のうちのいずれか1項に記載の方法。
- 前記酵素がアイソザイムである、請求項17から請求項22のうちのいずれか1項に記載の方法。
- 前記LSDがポンペ病であり、前記内因性酵素がα-グルコシダーゼ(GAA)であり、前記アイソザイムが、酸性α-グルコシダーゼ、スクラーゼ・イソマルターゼ(SI)、マルターゼ・グルコアミラーゼ(MGAM)、グルコシダーゼII(GANAB)、および中性α-グルコシダーゼ(C GNAC)からなる群から選択される、請求項23に記載の方法。
- 前記LSDがファブリー病であり、前記内因性酵素がα-ガラクトシダーゼA(GLA)であり、前記アイソザイムがGLA活性を得るように操作されたα-N-アセチルガラクトサミニダーゼである、請求項23に記載の方法。
- 前記膜タンパク質が、CD63、MHC-I、Kremen-1、Kremen-2、LRP5、LRP6、LRP8、トランスフェリン受容体、LDL-受容体、LDL関連タンパク質1受容体、ASGR1、ASGR2、アミロイド前駆体タンパク質様タンパク質-2(APLP2)、アペリン受容体(APLNR)、PRLR(プロラクチン受容体)、MAL(Myelin And Lymphocyteタンパク質、別名VIP17)、IGF2R、液胞型H+ATPアーゼ、ジフテリア毒素受容体、葉酸受容体、グルタミン酸受容体、グルタチオン受容体、レプチン受容体、スカベンジャー受容体、SCARA1-5、SCARB1-3、CD36、CDH16(Cadheri-16)、CLDN16(Claudn-16)、KL(Klotho)、PTH1R(副甲状腺ホルモン受容体)、SLC22A13(溶質輸送体ファミリー22メンバー13)、SLC5A2(ナトリウム/グルコース共輸送体2)、UMOD(ウロモジュリン)、BMPR1A(骨形態形成タンパク質受容体1A)、m-カドヘリン、CD9、MuSK(筋特異的キナーゼ)、LGR4/GPR48(Gタンパク質共役受容体48)、コリン作動性受容体(ニコチン性)アルファ1、CDH15(Cadheri-15)、ITGA7(インテグリンアルファ-7)、CACNG1(L型カルシウムチャネルサブユニットガンマ-1)、CACNAls(L型カルシウムチャネルサブユニットアルファ-15)、CACNG6(L型カルシウムチャネルサブユニットガンマ-6)、SCN1B(ナトリウムチャネルサブユニットベータ-1)、CHRNA1(ACh受容体サブユニットアルファ)、CHRND(ACh受容体サブユニットデルタ)、LRRC14B(ロイシンリッチリピート含有タンパク質14B)、およびPOPDC3(Popeyeドメイン含有タンパク質3)からなる群から選択される、請求項17から請求項25のうちのいずれか1項に記載の方法。
- 前記膜タンパク質がCD63である、請求項17から請求項26のうちのいずれか1項に記載の方法。
- 前記膜タンパク質がAPLP2である、請求項17から請求項26のうちのいずれか1項に記載の方法。
- 前記抗原結合タンパク質が、抗体、抗体断片、または他の抗原結合タンパク質である、請求項17から請求項28のうちのいずれか1項に記載の方法。
- 前記抗原結合タンパク質が、前記酵素と前記膜タンパク質とに結合する二重特異性抗体である、請求項29に記載の方法。
- 前記酵素がイムノグロブリンのFcドメインに連結しており、前記抗原結合タンパク質が半抗体を含む、請求項17から請求項29のうちのいずれか1項に記載の方法。
- 前記酵素が、抗膜タンパク質抗体の前記重鎖のC末端に共有結合している、請求項17から請求項29のうちのいずれか1項に記載の方法。
- 前記酵素が、抗膜タンパク質抗体の前記重鎖のN末端に共有結合している、請求項17から請求項29のうちのいずれか1項に記載の方法。
- 前記酵素がGLAを含み、前記膜タンパク質がCD63であり、および前記LSDがファブリー病である、請求項30に記載の方法。
- 前記酵素がGAAを含み、前記膜タンパク質がCD63であり、および前記LSDがポンペ病である、請求項30に記載の方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264702P | 2015-12-08 | 2015-12-08 | |
US62/264,702 | 2015-12-08 | ||
US201662379629P | 2016-08-25 | 2016-08-25 | |
US62/379,629 | 2016-08-25 | ||
JP2018529603A JP7065770B2 (ja) | 2015-12-08 | 2016-12-08 | 酵素の内部移行のための組成物および方法 |
PCT/US2016/065647 WO2017100467A2 (en) | 2015-12-08 | 2016-12-08 | Compositions and methods for internalizing enzymes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018529603A Division JP7065770B2 (ja) | 2015-12-08 | 2016-12-08 | 酵素の内部移行のための組成物および方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022058799A true JP2022058799A (ja) | 2022-04-12 |
Family
ID=57868326
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018529603A Active JP7065770B2 (ja) | 2015-12-08 | 2016-12-08 | 酵素の内部移行のための組成物および方法 |
JP2022012834A Pending JP2022058799A (ja) | 2015-12-08 | 2022-01-31 | 酵素の内部移行のための組成物および方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018529603A Active JP7065770B2 (ja) | 2015-12-08 | 2016-12-08 | 酵素の内部移行のための組成物および方法 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20190112588A1 (ja) |
EP (3) | EP3782639B1 (ja) |
JP (2) | JP7065770B2 (ja) |
KR (1) | KR20180084895A (ja) |
CN (2) | CN108367056B (ja) |
AU (2) | AU2016365834B2 (ja) |
BR (1) | BR112018011474A2 (ja) |
CA (1) | CA3006460A1 (ja) |
CY (1) | CY1123676T1 (ja) |
DK (2) | DK3782639T3 (ja) |
EA (1) | EA201891277A1 (ja) |
ES (2) | ES2833937T3 (ja) |
HU (2) | HUE060136T2 (ja) |
IL (2) | IL259714A (ja) |
MX (3) | MX2018007061A (ja) |
MY (1) | MY187933A (ja) |
NZ (1) | NZ743008A (ja) |
PH (1) | PH12018501074A1 (ja) |
PL (2) | PL3386534T3 (ja) |
PT (2) | PT3386534T (ja) |
SG (1) | SG11201804375WA (ja) |
WO (1) | WO2017100467A2 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3421488A3 (en) | 2012-03-14 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
WO2018132572A1 (en) | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin (rspo) surrogate molecules |
EP3574019A4 (en) | 2017-01-26 | 2021-03-03 | Surrozen, Inc. | TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF |
BR112019025888A2 (pt) * | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
EP3644722A1 (en) | 2017-06-27 | 2020-05-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
BR112020000273A2 (pt) * | 2017-07-07 | 2020-07-14 | Hanmi Pharm. Co., Ltd. | proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante |
WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
SG11202005510SA (en) * | 2017-12-22 | 2020-07-29 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having a novel structure and use thereof |
KR20200116952A (ko) * | 2018-02-05 | 2020-10-13 | 제이씨알 파마 가부시키가이샤 | 약제를 근육에 송달하기 위한 방법 |
WO2019157224A1 (en) * | 2018-02-07 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
CA3104868A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
US20210322562A1 (en) * | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
JP2021533197A (ja) * | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
MX2021001284A (es) | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y sus usos para el tratamiento de distrofia muscular facioescapulohumeral. |
WO2020132100A1 (en) | 2018-12-19 | 2020-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
CN116916947A (zh) | 2020-10-14 | 2023-10-20 | 戴纳立制药公司 | 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法 |
US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023016828A2 (en) * | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
TW202332767A (zh) | 2022-02-02 | 2023-08-16 | 美商雷傑納榮製藥公司 | 用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入 |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050158296A1 (en) * | 2002-01-11 | 2005-07-21 | Starr Christopher M. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
US10265412B2 (en) * | 2006-02-06 | 2019-04-23 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
ES2549121T3 (es) * | 2007-05-18 | 2015-10-23 | Tokyo Metropolitan Institute Of Medical Science | Composición farmacéutica para terapia de reemplazo enzimático |
SG189108A1 (en) * | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
HUE038172T2 (hu) * | 2011-05-27 | 2018-09-28 | Amicus Therapeutics Inc | Eljárások célzó peptidek rekombináns lizoszómális enzimekre történõ kapcsolására lizoszómális tárolási betegségek javított kezelésében |
SG10201600965YA (en) | 2011-10-28 | 2016-03-30 | Regeneron Pharma | Humanized il-6 and il-6 receptor |
EP3421488A3 (en) * | 2012-03-14 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
CN109053901A (zh) * | 2012-08-29 | 2018-12-21 | 霍夫曼-拉罗奇有限公司 | 血脑屏障穿梭体 |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
CA2962081A1 (en) * | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes useful to treat lysosomal storage disease |
WO2016065319A1 (en) * | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
MA41022A (fr) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
TWI769982B (zh) * | 2015-06-24 | 2022-07-11 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
BR112019025888A2 (pt) * | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
WO2019157224A1 (en) * | 2018-02-07 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
-
2016
- 2016-12-08 EP EP20197224.7A patent/EP3782639B1/en active Active
- 2016-12-08 DK DK20197224.7T patent/DK3782639T3/da active
- 2016-12-08 WO PCT/US2016/065647 patent/WO2017100467A2/en active Application Filing
- 2016-12-08 PT PT168293439T patent/PT3386534T/pt unknown
- 2016-12-08 ES ES16829343T patent/ES2833937T3/es active Active
- 2016-12-08 HU HUE20197224A patent/HUE060136T2/hu unknown
- 2016-12-08 KR KR1020187016730A patent/KR20180084895A/ko active Search and Examination
- 2016-12-08 MX MX2018007061A patent/MX2018007061A/es unknown
- 2016-12-08 AU AU2016365834A patent/AU2016365834B2/en active Active
- 2016-12-08 PL PL16829343T patent/PL3386534T3/pl unknown
- 2016-12-08 DK DK16829343.9T patent/DK3386534T3/da active
- 2016-12-08 BR BR112018011474A patent/BR112018011474A2/pt active Search and Examination
- 2016-12-08 MY MYPI2018701894A patent/MY187933A/en unknown
- 2016-12-08 HU HUE16829343A patent/HUE052155T2/hu unknown
- 2016-12-08 CN CN201680071498.8A patent/CN108367056B/zh active Active
- 2016-12-08 PL PL20197224.7T patent/PL3782639T3/pl unknown
- 2016-12-08 JP JP2018529603A patent/JP7065770B2/ja active Active
- 2016-12-08 SG SG11201804375WA patent/SG11201804375WA/en unknown
- 2016-12-08 EP EP16829343.9A patent/EP3386534B1/en active Active
- 2016-12-08 NZ NZ743008A patent/NZ743008A/en unknown
- 2016-12-08 PT PT201972247T patent/PT3782639T/pt unknown
- 2016-12-08 ES ES20197224T patent/ES2926280T3/es active Active
- 2016-12-08 EA EA201891277A patent/EA201891277A1/ru unknown
- 2016-12-08 CA CA3006460A patent/CA3006460A1/en active Pending
- 2016-12-08 EP EP22169278.3A patent/EP4074331A1/en active Pending
- 2016-12-08 US US15/781,681 patent/US20190112588A1/en active Pending
- 2016-12-08 CN CN202211577637.8A patent/CN116196400A/zh active Pending
-
2018
- 2018-05-18 PH PH12018501074A patent/PH12018501074A1/en unknown
- 2018-05-30 IL IL259714A patent/IL259714A/en unknown
- 2018-06-08 MX MX2023000731A patent/MX2023000731A/es unknown
- 2018-06-08 MX MX2022010490A patent/MX2022010490A/es unknown
-
2020
- 2020-12-22 CY CY20201101209T patent/CY1123676T1/el unknown
-
2021
- 2021-10-06 IL IL287019A patent/IL287019A/en unknown
-
2022
- 2022-01-31 JP JP2022012834A patent/JP2022058799A/ja active Pending
-
2023
- 2023-12-21 AU AU2023285891A patent/AU2023285891A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7065770B2 (ja) | 酵素の内部移行のための組成物および方法 | |
US20220195011A1 (en) | Compositions and methods for internalizing enzymes | |
CN109983031B (zh) | 通过血脑屏障的新的抗人转铁蛋白受体抗体 | |
US20200399623A1 (en) | Methods and compositions for therapeutic protein delivery | |
US20180009904A1 (en) | Lysosomal targeting and uses thereof | |
RU2806021C2 (ru) | Композиции и способы для интернализации ферментов | |
EA041885B1 (ru) | Композиции и способы интернализации ферментов | |
RU2818779C2 (ru) | Способы и композиции для доставки терапевтического белка | |
TW202346348A (zh) | 作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230515 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240528 |